New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:07 EDTOMEROmeros price target lowered to $16 from $19 at Burrill
Burrill lowered its price target for Omeros after the company announced that OMS103HP did not meet its primary endpoint in patients undergoing arthroscopic partial meniscectomy surgery. The firm notes that OMS103HP achieved statistically significant reduction of postoperative pain, though, and keeps an Outperform rating on the stock.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
16:23 EDTOMEROmeros sees FY15 OpEx $110M-$120M
For 2015, the company anticipates that operating expenses will be in the $110M-$120M range with non-cash expenses of approximately $15M. This guidance is largely based on the continued preparations for the full-scale U.S. launch of Omidria as well as the continued development of the company's product pipeline.
16:22 EDTOMEROmeros reports Q4 EPS (61c) with items, consensus (62c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use